Heron Therapeutics Inc. (NASDAQ:HRTX) – Research analysts at Leerink Swann cut their FY2016 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Thursday. Leerink Swann analyst J. Gerberry now anticipates that the firm will post earnings of ($4.06) per share for the year, down from their previous estimate of ($4.01). Leerink Swann currently has a “Buy” rating and a $34.00 target price on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($0.92) EPS, FY2017 earnings at ($2.31) EPS, FY2018 earnings at ($1.15) EPS, FY2019 earnings at $1.07 EPS and FY2020 earnings at $4.62 EPS.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

A number of other equities research analysts have also recently weighed in on the company. Jefferies Group restated a “buy” rating and issued a $46.00 price target on shares of Heron Therapeutics in a research note on Wednesday, July 27th. Brean Capital restated a “buy” rating and issued a $55.00 price target on shares of Heron Therapeutics in a research note on Saturday, August 13th. Cantor Fitzgerald restated a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a research note on Wednesday, August 3rd. Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 31st. Finally, Lake Street Capital restated a “buy” rating and issued a $45.00 price target on shares of Heron Therapeutics in a research note on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $42.29.

Heron Therapeutics (NASDAQ:HRTX) opened at 17.20 on Monday. Heron Therapeutics has a 52-week low of $15.13 and a 52-week high of $31.32. The stock has a 50 day moving average of $18.51 and a 200-day moving average of $18.93.

In related news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the transaction, the insider now owns 102,640 shares in the company, valued at $2,391,512. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.31% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of HRTX. Franklin Resources Inc. boosted its position in shares of Heron Therapeutics by 3.0% in the second quarter. Franklin Resources Inc. now owns 7,752,460 shares of the biotechnology company’s stock worth $139,937,000 after buying an additional 229,182 shares during the last quarter. FMR LLC boosted its position in shares of Heron Therapeutics by 1.2% in the second quarter. FMR LLC now owns 5,493,420 shares of the biotechnology company’s stock worth $99,156,000 after buying an additional 63,968 shares during the last quarter. Janus Capital Management LLC boosted its position in shares of Heron Therapeutics by 14.8% in the second quarter. Janus Capital Management LLC now owns 4,013,921 shares of the biotechnology company’s stock worth $72,450,000 after buying an additional 516,166 shares during the last quarter. Cormorant Asset Management LLC boosted its position in shares of Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock worth $33,233,000 after buying an additional 64,281 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Heron Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 1,215,343 shares of the biotechnology company’s stock worth $21,937,000 after buying an additional 58,039 shares during the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.